Skip to content

Study · Not a test of the peptide alone · 2025

2 results

Synergistic Effects of Injectable Platelet-Rich Fibrin and Bioactive Peptides on Dermal Fibroblast Viability and Extracellular Matrix Gene Expression: An In Vitro Study.

Paccola AGL, Santos TMCD, Minelo MC, Garbieri TF, Sanches MLR, Dionísio TJ, Oliveira RC, Santos CF, Buzalaf MAR

Molecules (Basel, Switzerland)19 Aug 2025Cited by 3 (Europe PMC)

PMID40871567 (opens in a new tab)PMCIDPMC12388378 (opens in a new tab)DOI10.3390/molecules30163415 (opens in a new tab)PepBankPUB-40871567
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Facial aging is a multifactorial process involving changes in bone, fat compartments, ligaments, muscles, and skin. Collagen biostimulators, including synthetic agents and autologous platelet concentrates, have gained attention for facial rejuvenation. Injectable platelet-rich fibrin (i-PRF), a second-generation autologous concentrate, has shown promising regenerative properties due to its natural composition and growth factors. Cosmetic peptides, such as palmitoyl pentapeptide-4 (Matrixyl) and Tetrapeptide-21 (GEKG), are also studied for their ability to stimulate collagen synthesis and remodel the extracellular matrix. This in vitro study examined the potential synergistic effects of i-PRF combined with Matrixyl or GEKG on human dermal fibroblast viability, proliferation, and ECM-related gene expression. Fibroblasts were cultured under six conditions: control, i-PRF alone, Matrixyl alone, GEKG alone, i-PRF + Matrixyl, and i-PRF + GEKG. Viability and proliferation were assessed via MTT, crystal violet, and RealTime-Glo™ assays. Gene expression of COL1A1, FN1, and HAS1 was measured using RT-qPCR. The combinations, especially i-PRF + GEKG, led to increased cell viability and upregulated ECM-related genes at 72 h. These effects were stronger than the individual treatments, suggesting synergistic effects, especially with GEKG. These findings highlight the clinical potential of combining autologous platelet concentrates with bioactive peptides for dermal regeneration. Further preclinical and clinical studies are warranted.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  1. 01LabNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneIn vitro (cells)Efficacy outcome

    In human fibroblasts, pooled i-PRF-peptide combinations, including Matrixyl, increased viability beyond individual treatments, especially with GEKG.

    In plain wordsIn cells, pooled i-PRF-peptide combinations, including Matrixyl, increased viability more than individual treatments, especially with GEKG.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    IncreaseCell viability
    Study

    humann: not reported in source

    Human dermal fibroblasts
    Comparator
    Individual treatments
    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    The combinations, especially i-PRF + GEKG, led to increased cell viability and upregulated ECM-related genes at 72 h. These effects were stronger than the individual treatments, suggesting synergistic effects, especially with GEKG.
    1 context sentence
    Summary · context
    This in vitro study examined the potential synergistic effects of i-PRF combined with Matrixyl or GEKG on human dermal fibroblast viability, proliferation, and ECM-related gene expression. Fibroblasts were cultured under six conditions: control, i-PRF alone, Matrixyl alone, GEKG alone, i-PRF + Matrixyl, and i-PRF + GEKG.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  2. 02LabNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneIn vitro (cells)Mechanism

    In human fibroblasts, pooled i-PRF-peptide combinations, including Matrixyl, increased ECM-related gene expression beyond individual treatments, especially with GEKG.

    In plain wordsIn cells, pooled i-PRF-peptide combinations, including Matrixyl, increased matrix-related gene expression more than individual treatments, especially with GEKG.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    IncreaseECM-related gene expression
    Study

    humann: not reported in source

    Human dermal fibroblasts
    Comparator
    Individual treatments
    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    The combinations, especially i-PRF + GEKG, led to increased cell viability and upregulated ECM-related genes at 72 h. These effects were stronger than the individual treatments, suggesting synergistic effects, especially with GEKG.
    1 context sentence
    Summary · context
    This in vitro study examined the potential synergistic effects of i-PRF combined with Matrixyl or GEKG on human dermal fibroblast viability, proliferation, and ECM-related gene expression. Fibroblasts were cultured under six conditions: control, i-PRF alone, Matrixyl alone, GEKG alone, i-PRF + Matrixyl, and i-PRF + GEKG.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.